secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001193125-24-151729
Event type: regulatory
Sentiment:  negative
Materiality: 0.55
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos receives Nasdaq notice for Audit Committee noncompliance; cure period to Nov 2024
--------------------------------------------------------------------------------

- Jack Nielsen resigned from Board and Audit Committee on May 21, 2024, causing noncompliance with Rule 5605.
- Nasdaq granted cure period until Nov 18, 2024, as next annual meeting is June 27, 2024.
- Company plans to appoint a third independent director to the Audit Committee before the cure deadline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524151729/0001193125-24-151729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524151729/d808483d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-151729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer